Dr. Bekaii-Saab on the Impact of the BEACON CRC Study in BRAF-Mutated CRC

Tanios Bekaii-Saab, MD
Published: Wednesday, Jun 12, 2019



Tanios S. Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the phase III BEACON CRC trial in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).

The field of mCRC is starting to adopt more of a precision medicine approach, Bekaii-Saab says. Researchers have a better understanding of the role of BRAF, HER2, and RAS, although there are not yet any RAS-targeted therapies. Significant progress has been made in the BRAF space, where patients traditionally had a very poor prognosis with very limited options.

The BEACON CRC study, which looked at the triplet regimen of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux), led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E mutations. Response rates also increased from about 2% with the combination of chemotherapy and cetuximab to approximately 27% with the triplet. This is a transformative study because this patient population had very little benefit from chemotherapy and zero benefit from EGFR inhibition.
SELECTED
LANGUAGE


Tanios S. Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the phase III BEACON CRC trial in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).

The field of mCRC is starting to adopt more of a precision medicine approach, Bekaii-Saab says. Researchers have a better understanding of the role of BRAF, HER2, and RAS, although there are not yet any RAS-targeted therapies. Significant progress has been made in the BRAF space, where patients traditionally had a very poor prognosis with very limited options.

The BEACON CRC study, which looked at the triplet regimen of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux), led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E mutations. Response rates also increased from about 2% with the combination of chemotherapy and cetuximab to approximately 27% with the triplet. This is a transformative study because this patient population had very little benefit from chemotherapy and zero benefit from EGFR inhibition.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x